Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 163

1.

Switch maintenance chemotherapy using S-1 with or without bevacizumab in patients with advanced non-small cell lung cancer: a phase II study.

Niho S, Ohe Y, Ohmatsu H, Umemura S, Matsumoto S, Yoh K, Goto K.

Lung Cancer. 2017 Jun;108:66-71. doi: 10.1016/j.lungcan.2017.02.018. Epub 2017 Mar 1.

PMID:
28625650
2.

IL-32 induces indoleamine 2,3-dioxygenase+CD1c+ dendritic cells and indoleamine 2,3-dioxygenase+CD163+ macrophages: Relevance to mycosis fungoides progression.

Ohmatsu H, Humme D, Gonzalez J, Gulati N, Möbs M, Sterry W, Krueger JG.

Oncoimmunology. 2016 May 5;6(2):e1181237. doi: 10.1080/2162402X.2016.1181237. eCollection 2017.

3.

Prognostic Factor Analysis in Patients With Small-Cell Lung Cancer Treated With Third-Line Chemotherapy.

Saruwatari K, Umemura S, Nomura S, Kirita K, Matsumoto S, Yoh K, Niho S, Ohmatsu H, Ohe Y, Goto K.

Clin Lung Cancer. 2016 Nov;17(6):581-587. doi: 10.1016/j.cllc.2016.05.022. Epub 2016 Jun 16.

PMID:
27424806
4.

Changes in the tumor microenvironment during lymphatic metastasis of lung squamous cell carcinoma.

Ikemura S, Aramaki N, Fujii S, Kirita K, Umemura S, Matsumoto S, Yoh K, Niho S, Ohmatsu H, Kuwata T, Kojima M, Ochiai A, Betsuyaku T, Tsuboi M, Goto K, Ishii G.

Cancer Sci. 2017 Jan;108(1):136-142. doi: 10.1111/cas.13110. Epub 2017 Jan 21.

5.

Successful treatment with afatinib after grade 3 hepatotoxicity induced by both gefitinib and erlotinib in EGFR mutation-positive non-small cell lung cancer.

Zenke Y, Umemura S, Sugiyama E, Kirita K, Matsumoto S, Yoh K, Niho S, Ohmatsu H, Goto K.

Lung Cancer. 2016 Sep;99:1-3. doi: 10.1016/j.lungcan.2016.05.002. Epub 2016 Jun 6.

PMID:
27565905
6.

Genomic Profiling of Large-Cell Neuroendocrine Carcinoma of the Lung.

Miyoshi T, Umemura S, Matsumura Y, Mimaki S, Tada S, Makinoshima H, Ishii G, Udagawa H, Matsumoto S, Yoh K, Niho S, Ohmatsu H, Aokage K, Hishida T, Yoshida J, Nagai K, Goto K, Tsuboi M, Tsuchihara K.

Clin Cancer Res. 2017 Feb 1;23(3):757-765. doi: 10.1158/1078-0432.CCR-16-0355. Epub 2016 Aug 9.

PMID:
27507618
7.

A phase I dose-escalation study of LY2875358, a bivalent MET antibody, given as monotherapy or in combination with erlotinib or gefitinib in Japanese patients with advanced malignancies.

Yoh K, Doi T, Ohmatsu H, Kojima T, Takahashi H, Zenke Y, Wacheck V, Enatsu S, Nakamura T, Turner K, Uenaka K.

Invest New Drugs. 2016 Oct;34(5):584-95. doi: 10.1007/s10637-016-0370-7. Epub 2016 Sep 1.

8.

Discrimination of Dysplastic Nevi from Common Melanocytic Nevi by Cellular and Molecular Criteria.

Mitsui H, Kiecker F, Shemer A, Cannizzaro MV, Wang CQF, Gulati N, Ohmatsu H, Shah KR, Gilleaudeau P, Sullivan-Whalen M, Cueto I, McNutt NS, Suárez-Fariñas M, Krueger JG.

J Invest Dermatol. 2016 Oct;136(10):2030-2040. doi: 10.1016/j.jid.2015.11.035. Epub 2016 Jul 1.

9.

A CASE OF UNILATERAL RETINAL PIGMENT EPITHELIUM DYSGENESIS.

Yamasaki A, Tominaga T, Ishikura R, Ohmatsu H, Inoue Y.

Retin Cases Brief Rep. 2017 Spring;11(2):156-159. doi: 10.1097/ICB.0000000000000317.

PMID:
27124794
10.

Acute and Progressive Tracheal Stenosis after Proton Beam Therapy with Concurrent Chemotherapy for Non-Small Cell Lung Cancer.

Zenke Y, Umemura S, Motegi A, Furukawa K, Kirita K, Matsumoto S, Yoh K, Niho S, Ohmatsu H, Tsuboi M, Akimoto T, Goto K.

J Thorac Oncol. 2016 Jul;11(7):1181-3. doi: 10.1016/j.jtho.2016.04.011. Epub 2016 Apr 22. No abstract available.

11.

Natural History of Pulmonary Subsolid Nodules: A Prospective Multicenter Study.

Kakinuma R, Noguchi M, Ashizawa K, Kuriyama K, Maeshima AM, Koizumi N, Kondo T, Matsuguma H, Nitta N, Ohmatsu H, Okami J, Suehisa H, Yamaji T, Kodama K, Mori K, Yamada K, Matsuno Y, Murayama S, Murata K.

J Thorac Oncol. 2016 Jul;11(7):1012-28. doi: 10.1016/j.jtho.2016.04.006. Epub 2016 Apr 16.

12.

Factors influencing the concordance of histological subtype diagnosis from biopsy and resected specimens of lung adenocarcinoma.

Matsuzawa R, Kirita K, Kuwata T, Umemura S, Matsumoto S, Fujii S, Yoh K, Kojima M, Niho S, Ohmatsu H, Ochiai A, Tsuboi M, Goto K, Ishii G.

Lung Cancer. 2016 Apr;94:1-6. doi: 10.1016/j.lungcan.2016.01.009. Epub 2016 Jan 22.

PMID:
26973199
13.

Clinical Impact of Gastric Acid-Suppressing Medication Use on the Efficacy of Erlotinib and Gefitinib in Patients With Advanced Non-Small-Cell Lung Cancer Harboring EGFR Mutations.

Zenke Y, Yoh K, Matsumoto S, Umemura S, Niho S, Ohmatsu H, Goto K, Ohe Y.

Clin Lung Cancer. 2016 Sep;17(5):412-418. doi: 10.1016/j.cllc.2016.01.006. Epub 2016 Feb 5.

PMID:
26944770
15.

Aggressive tumor microenvironment of solid predominant lung adenocarcinoma subtype harboring with epidermal growth factor receptor mutations.

Saruwatari K, Ikemura S, Sekihara K, Kuwata T, Fujii S, Umemura S, Kirita K, Matsumoto S, Yoh K, Niho S, Ohmatsu H, Ochiai A, Kohrogi H, Tsuboi M, Goto K, Ishii G.

Lung Cancer. 2016 Jan;91:7-14. doi: 10.1016/j.lungcan.2015.11.012. Epub 2015 Nov 15.

PMID:
26711928
16.

RECIST progression patterns during EGFR tyrosine kinase inhibitor treatment of advanced non-small cell lung cancer patients harboring an EGFR mutation.

Yoshida T, Yoh K, Niho S, Umemura S, Matsumoto S, Ohmatsu H, Ohe Y, Goto K.

Lung Cancer. 2015 Dec;90(3):477-83. doi: 10.1016/j.lungcan.2015.09.025. Epub 2015 Oct 9.

PMID:
26604031
17.

Unique intravascular tumor microenvironment predicting recurrence of lung squamous cell carcinoma.

Hisakane K, Saruwatari K, Fujii S, Kirita K, Umemura S, Matsumoto S, Yoh K, Niho S, Ohmatsu H, Kuwata T, Ochiai A, Gemma A, Tsuboi M, Goto K, Ishii G.

J Cancer Res Clin Oncol. 2016 Mar;142(3):593-600. doi: 10.1007/s00432-015-2068-1. Epub 2015 Oct 31.

PMID:
26521256
18.

Impact of single nucleotide polymorphisms on severe hepatotoxicity induced by EGFR tyrosine kinase inhibitors in patients with non-small cell lung cancer harboring EGFR mutations.

Sugiyama E, Umemura S, Nomura S, Kirita K, Matsumoto S, Yoh K, Niho S, Ohmatsu H, Tsuboi M, Ohe Y, Goto K.

Lung Cancer. 2015 Nov;90(2):307-13. doi: 10.1016/j.lungcan.2015.08.004. Epub 2015 Aug 12.

PMID:
26323212
19.

Phase II study of amrubicin at a dose of 45 mg/m2 in patients with previously treated small-cell lung cancer.

Asao T, Nokihara H, Yoh K, Niho S, Goto K, Ohmatsu H, Kubota K, Yamamoto N, Sekine I, Kunitoh H, Fujiwara Y, Ohe Y.

Jpn J Clin Oncol. 2015 Oct;45(10):941-6. doi: 10.1093/jjco/hyv107. Epub 2015 Jul 31.

PMID:
26232449
20.

Second-line docetaxel for patients with platinum-refractory advanced non-small cell lung cancer and interstitial pneumonia.

Watanabe N, Niho S, Kirita K, Umemura S, Matsumoto S, Yoh K, Ohmatsu H, Goto K.

Cancer Chemother Pharmacol. 2015 Jul;76(1):69-74. doi: 10.1007/s00280-015-2775-y. Epub 2015 May 15.

PMID:
25976217

Supplemental Content

Loading ...
Support Center